Odyssey Group International, Inc. (OTCQB:ODYY) Hits Milestone in its Quest for Concussion Treatment

March 5, 2020 -- InvestorsHub NewsWire -- via Envivo Consulting International -- After the January missile attack on their base in Iraq, more than 100 US troops were diagnosed with a traumatic brain injury (TBI), and that is only a fraction of the over 400,000 reported by the Department of Defense since 2000. The military has had to take a deeper look at the effects of these TBIs, much like the NFL was forced to do after mounting evidence showed a link between repetitive head trauma and the development in an increasing number of their players of chronic traumatic encephalopathy (CTE), a degenerative brain disorder.

March is TBI Awareness Month, but concussions, which are considered a mild TBI (mTBI), have become a major public health issue garnering attention year-round. Some even call it an epidemic. Concussions affect many groups, including the elderly whose likelihood of dementia more than doubles after experiencing an mTBI. Although they are usually not life-threatening, there is no doubt that the repercussions of an untreated concussion can be devastating and long-term.

Fortunately, there are a few companies that have been researching more effective ways of diagnosing and treating them. One of these is Odyssey Group International, Inc. (OTCQB:ODYY) a technology and asset acquisition company focused on developing unique, life-saving medical products. In partnership with biopharmaceutical Prevacus, Inc., they have been developing Prevasol, a neuro-steroid drug for the immediate treatment of concussions.

Prevacus recently announced the completion of GMP certification of API for PRV-002, a new chemical entity that readily passes the blood-brain barrier and is their lead compound for treating concussions acutely. This certification will allow them to start their first human trials once their final nano-formulation for nasal application is prepared.

The nasal spray can be administered by a trainer, medic, or first responder as soon as possible when a brain injury occurs. It takes less than five minutes to get into the brain, and within thirty minutes the drug diffuses through all areas of the brain- reducing swelling, inflammation, and oxidative stress.

Drugs of this genre are of special interest to NFL players since the treatment could lower the chances they’ll have to deal with the depression, memory loss, and mood disorders that come with CTE. In fact, Prevacus has already received endorsements from 3 Super Bowl MVP quarterbacks, including Brett Favre, Kurt Warner and Mark Rypien, as well as soccer sports legend Abby Wambach.

The benefits are not just medical. The average cost to treat a concussion is currently about $12,000, but Prevasol would likely cost patients under $300 post-insurance. Company founder, Jake VanLandingham, expects Prevacus to save $3-4 billion in healthcare costs.

To ensure the consistent quality of its products, Odyssey announced it signed an agreement with Majic LLC, a Systems Engineering company that specializes in ensuring medical devices are integrated properly and address all regulatory requirements. Majik will assist Odyssey on its other products, CardioMap and Save-a-Life choking rescue device.

Disclaimer:

Envivo Consulting International (ECI) is compensated, either directly or via a third party, to provide investor relations services for its clients. ECI creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled or is available from public sources. ECI and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that ECI believes to be reliable, but its accuracy is not guaranteed. ECI may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. ECI was compensated three thousand dollars for the creation and dissemination of this content by the company.
This material does not represent a solicitation to buy or sell any securities. Certain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company's plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company's industry, management's beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
ECI and its affiliates, officers, directors, and employees have not bought or sold and will not buy or sell shares in the companies discussed herein.

Source: Envivo Consulting International